WO2007034851A1 - 内臓脂肪蓄積抑制剤 - Google Patents
内臓脂肪蓄積抑制剤 Download PDFInfo
- Publication number
- WO2007034851A1 WO2007034851A1 PCT/JP2006/318685 JP2006318685W WO2007034851A1 WO 2007034851 A1 WO2007034851 A1 WO 2007034851A1 JP 2006318685 W JP2006318685 W JP 2006318685W WO 2007034851 A1 WO2007034851 A1 WO 2007034851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- visceral fat
- compound
- fat accumulation
- plant
- extract
- Prior art date
Links
- 210000001596 intra-abdominal fat Anatomy 0.000 title claims description 104
- 238000009825 accumulation Methods 0.000 title claims description 80
- 239000003112 inhibitor Substances 0.000 title claims description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 239000000284 extract Substances 0.000 claims abstract description 41
- 235000013305 food Nutrition 0.000 claims abstract description 41
- 241000196324 Embryophyta Species 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- 241000234280 Liliaceae Species 0.000 claims abstract description 14
- 235000013361 beverage Nutrition 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 15
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 15
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 6
- UXBAUUVEYYMRCL-QPEZSDMJSA-N (2r,3r,4s,5s,6r)-2-[[(9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)[C@H](C)CC[C@H](C)C(C)C)=CCC1C(C)C2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UXBAUUVEYYMRCL-QPEZSDMJSA-N 0.000 abstract 1
- UXBAUUVEYYMRCL-UHFFFAOYSA-N 3-O-beta-D-glucopyranosyl-4-methyl-ergost-7-en-3-ol Natural products C1CC2(C)C3CCC4(C)C(C(C)CCC(C)C(C)C)CCC4C3=CCC2C(C)C1OC1OC(CO)C(O)C(O)C1O UXBAUUVEYYMRCL-UHFFFAOYSA-N 0.000 abstract 1
- 208000004611 Abdominal Obesity Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 235000011399 aloe vera Nutrition 0.000 description 36
- 238000012360 testing method Methods 0.000 description 33
- 208000008589 Obesity Diseases 0.000 description 32
- 235000020824 obesity Nutrition 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 235000002961 Aloe barbadensis Nutrition 0.000 description 28
- 244000186892 Aloe vera Species 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229940125904 compound 1 Drugs 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 235000019786 weight gain Nutrition 0.000 description 12
- AOQRDALGACAKHI-KVCRWQBISA-N (9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC21 AOQRDALGACAKHI-KVCRWQBISA-N 0.000 description 11
- AOQRDALGACAKHI-UHFFFAOYSA-N 4-methylergost-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(C)C(C)C)CCC33)C)C3=CCC21 AOQRDALGACAKHI-UHFFFAOYSA-N 0.000 description 11
- 239000000287 crude extract Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- -1 β-sitosterol monole Chemical compound 0.000 description 9
- 241001116389 Aloe Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012156 elution solvent Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000020805 dietary restrictions Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000006140 methanolysis reaction Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000002378 plant sterols Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 240000007474 Aloe arborescens Species 0.000 description 2
- 235000004509 Aloe arborescens Nutrition 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- AYLGEPGGWRFUQH-QNHMXKJYSA-N (3S,6R)-2,3-dimethyl-6-[(9R,10S,13R,14R,17R)-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]heptan-1-ol Chemical compound CC1C2CC=C3[C@@H]4CC[C@H]([C@@H](CC[C@@H](C(CO)C)C)C)[C@]4(CC[C@@H]3[C@]2(CCC1)C)C AYLGEPGGWRFUQH-QNHMXKJYSA-N 0.000 description 1
- LTSWUFKUZPPYEG-UHFFFAOYSA-N 1-decoxydecane Chemical compound CCCCCCCCCCOCCCCCCCCCC LTSWUFKUZPPYEG-UHFFFAOYSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 241001073152 Aloe africana Species 0.000 description 1
- 244000101643 Aloe ferox Species 0.000 description 1
- 235000015858 Aloe ferox Nutrition 0.000 description 1
- 241000782139 Aloe spicata Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZVVIENXDGJBDEH-SRWQUNOTSA-N CC1C2CC=C3[C@@H]4CC[C@H]([C@@H](CC[C@@H](C(=CO)C)C)C)[C@]4(CC[C@@H]3[C@]2(CCC1)C)C Chemical group CC1C2CC=C3[C@@H]4CC[C@H]([C@@H](CC[C@@H](C(=CO)C)C)C)[C@]4(CC[C@@H]3[C@]2(CCC1)C)C ZVVIENXDGJBDEH-SRWQUNOTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 1
- 229940008102 alloin Drugs 0.000 description 1
- AFHJQYHRLPMKHU-CGISPIQUSA-N aloin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-CGISPIQUSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021130 excess caloric intake Nutrition 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a visceral fat accumulation inhibitor containing 3-0- ⁇ -D-darcoviranosyl 4-methylergost-7-enol as an active ingredient, and a food or drink containing the same. More specifically, a visceral fat accumulation inhibitor capable of reducing fat accumulated in the abdominal cavity and preventing or improving visceral fat-type obesity, which is considered to be a major cause of metabolic syndrome, and the viscera It relates to functional foods and beverages such as foods for specified health use that contain fat accumulation inhibitors.
- Obesity refers to excessive energy accumulation due to a decrease in calories consumed due to excess calorie intake and lack of exercise, etc., and refers to ⁇ a state in which adipose tissue (body fat) in the body has accumulated excessively '' It has been pointed out that it is the basis for the development of so-called lifestyle-related diseases such as diabetes, hypertension, and hyperlipidemia.
- Adipose tissue includes subcutaneous fat that accumulates under the skin and visceral fat that accumulates around the internal organs of the abdominal cavity. These are collectively referred to as body fat.
- body fat As obesity, subcutaneous fat type obesity in which subcutaneous fat is accumulated and visceral fat type obesity in which visceral fat accumulates are known. In particular, accumulation of visceral fat is caused by abnormal metabolism in obesity such as cardiovascular disease. It strongly affects the frequency and severity of complications.
- Non-patent Document 3 The diagnostic criteria for metabolic syndrome proposed in Japan in April 2005 are the body mass index (BMI), which is usually used as a measure of the degree of obesity, and the visceral fat area 100 cm 2 which is not the body fat percentage.
- BMI body mass index
- the waist circumference equivalent to the above was adopted as an essential item, and it was established that visceral fat accumulation was deeply related to the cause of metabolic syndrome.
- Plant cholesterol such as ⁇ -sitosterol monole, campesterol, and stigmasterol
- a metabolic improving agent (Patent Document 1) is disclosed.
- an anti-obesity agent and a lipid metabolism improving agent containing cholesterone compound synthesized using plant sterols such as j8-sitosterol and campesterol as starting materials, or 4-cholesten 3one as an active ingredient (Patent Documents 2 to 5).
- Patent Document 1 Japanese Patent Laid-Open No. 2005-15425
- Patent Document 2 JP-A-7-165587
- Patent Document 3 Japanese Patent Laid-Open No. 11-193296
- Patent Document 4 Japanese Patent Laid-Open No. 2001-240544
- Patent Document 5 JP-A-5-170651
- Patent Document 6 Japanese Unexamined Patent Publication No. 2000-319190
- Patent Document 7 New Zealand Patent No. 330439
- Patent Document 8 US Patent No. 6280751
- Non-patent document 1 Journal of Applied Physiology, 95th, 1728-: L736, 2003
- Non-Patent Document 2 Journal 'Ob' Applied 'Physiology, 99th, 1220-1225, 2005
- Non-Patent Document 3 Adiposcience, Vol. 2, pp. 11-15, 2005
- Non-Patent Document 4 Medicine and Biology, Vol. 125, No. 5, pp. 189-194
- Non-Patent Document 5 Journal of Fujita Gakuen Medical Society, No.22, No.2, pp.153-157
- Patent Document 1 does not describe the effects of administration of plant sterols alone, but has no description or suggestion of any action on visceral fat.
- the 3-ketosteroid compound disclosed in Patent Document 2 the cholesterol compound disclosed in Patent Document 3, and the 24-methylcholestone compound disclosed in Patent Document 4. It has been disclosed that compounds of 24 alkylcholestene 3-one compounds such as 3-one also have the effect of reducing body weight, body fat mass and blood lipid mass, but oral intake Suppressing visceral fat accumulation without affecting weight gain or weight gain As a result, there was no mention or suggestion of the effect.
- Patent Document 5 The 4 cholesterol 3-one disclosed in Patent Document 5 is clearly different from the effective component of the present invention.
- a normal mouse is ingested calories, it has been shown to have an effect of reducing the fat content within the normal range more than necessary together with the excess intraperitoneal fat.
- the effect of effectively suppressing only the fat accumulated more than necessary in the internal organs during the intake of various calories was clearly different.
- the obesity prevention / amelioration agent described in Patent Document 6 is effective in suppressing the progression of obesity associated with weight gain and maintaining a standard weight without requiring excessive dietary restriction.
- the active ingredient described in Patent Document 6 is an aloe extract. There is no specific component involved in inhibiting the progression of obesity associated with weight gain, and weight is a different effect. When visceral fat is reduced without a decrease, it is difficult to predict the descriptive power of Patent Document 6, including the presence of the visceral fat accumulation inhibitory effect.
- a first invention of the present application for solving the above-mentioned problems is a visceral fat accumulation inhibitor containing a compound represented by the following chemical formula (1) as an active ingredient.
- the second invention of the present application for solving the above-mentioned problem is a plant organic solvent extract, a hot water extract, or a compressed solution containing a compound represented by the following chemical formula (1), or a fraction thereof:
- a third invention of the present application for solving the above-mentioned problems is a food or drink containing the visceral fat accumulation inhibitor described in the first or second invention, wherein the compound is represented by the chemical formula (1). Is preferably contained in an amount of 0.0001% by mass or more.
- the fourth invention of the present application for solving the above-mentioned problems is a compound represented by the above chemical formula (1) for the production of a visceral fat accumulation inhibitor, or at least 0.001 mass by mass of the compound.
- the fifth invention of the present application for solving the above-mentioned problems is a method for suppressing the accumulation of visceral fat, wherein the compound represented by the chemical formula (1) or the compound is at least 0.001 mass by dry mass. % Of the plant organic solvent extract, hot water extract, compressed solution, or fraction thereof, to a subject whose visceral fat accumulation is to be suppressed.
- the plant is a lily family.
- the visceral fat accumulation inhibitor of the present invention and foods and drinks containing the same can be safely administered or taken, and have an action of effectively suppressing the accumulation of visceral fat.
- the active ingredient of the visceral fat accumulation inhibitor of the present invention can be easily produced from lily family plants such as Aloe barbadensis Miller, which can be safely ingested and easily obtained from dietary experience.
- the visceral fat accumulation inhibitory action means an action of reducing the amount of fat accumulated in the abdominal cavity. Therefore, the visceral fat accumulation inhibitory action can be evaluated by measuring the amount of fat in the abdominal cavity, for example, the weight of mesenteric fat.
- the compound (hereinafter also referred to as “the compound of the present invention”) used as an active ingredient of the visceral fat accumulation inhibitor of the present invention (hereinafter also referred to as “the pharmaceutical of the present invention! /”) Is represented by the general formula ( It is a compound having the structure represented by 1), that is, 3-0- ⁇ D-darcobilanosyl 4-methylergost 7-en-3-ol.
- the compound of the present invention has a structure in which the hydroxyl group at the 3-position of 4-methylergost-7-enenol and the hydroxyl group at the 1-position of D-glucose are dehydrated and condensed.
- a composition used as an active ingredient of the visceral fat accumulation inhibitor of the present invention contains at least 0.001 of the compound of the present invention in a dry mass.
- the upper limit of the content of the compound of the present invention is not particularly limited, but 10% by mass is preferably 50% by mass, 70% by mass, or 90% by mass.
- the dry mass refers to the dry mass defined in the general test method "Dehydration Loss Test Method" in the 14th revised Japanese Pharmacopoeia (Ministry of Health, Labor and Welfare Notification No. 111, March 30, 2001).
- the mass measured after the compound was dried.For example, about 1 lg of the compound of the present invention was collected, dried at 105 ° C. for 4 hours, allowed to cool in a desiccator, and measured with a balance. It can be defined by measuring its mass.
- the compound of the present invention or a composition containing the same belongs to, for example, a lily family plant, and a fraction containing the compound is removed from a plant containing the compound of the present invention or a part thereof or a crushed product thereof with an organic solvent. Or it can manufacture by extracting and concentrating using hot water.
- Examples of the plant belonging to the lily family include plants belonging to the genus Aloe or Allium. Aloe vera (Aloe barbadensis Miller), Aloe fex rocks mirror (Aloe ferox Miller), Aloe african namiller (Aloe africana Miller), Kis Examples include Dati aloe (Aloe arborescen Miller var. Natalensis Berger) and Aloe spicata Baker. In the production of the compound of the present invention or the composition containing the same, the whole plant may be used, but it is preferable to use mesophyll (transparent gel portion).
- Such a plant or a part thereof is preferably crushed by using a homogenizer or the like, liquefied, and extracted with an organic solvent or hot water.
- organic solvent include alcohols such as methanol, ethanol, and butanol; esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate; ketones such as acetone and methyl isobutyl ketone; ethers such as jetyl ether and petroleum ether; Hydrocarbons such as cyclohexane, toluene, benzene, etc .; Halogenated hydrocarbons such as tetrasalt carbon, dichloromethane, chloroform, etc .; Heterocyclic compounds such as pyridine, Daricols such as ethylene glycol; Polyalcohols such as polyethylene glycol A -tolyl solvent such as acetonitrile, and a mixed solution of these solvents. These solvents may be anhydr
- an extraction method a method used for extraction of normal plant components can be used. Usually, 1 to 300 parts by mass of an organic solvent is used per 1 part by mass of a fresh or dried plant, and the mixture is heated to reflux at a temperature not higher than the boiling point of the solvent while stirring or shaking, or is subjected to ultrasonic extraction at room temperature. A method is mentioned.
- the crude extract can be obtained by separating the insoluble matter by an appropriate method such as filtration or centrifugation.
- the crude extract can be purified by various chromatographic methods such as normal phase or reverse phase silica gel column chromatography.
- the compound obtained as described above or the compositional power comprising the same includes, for example, an indicator of an inhibitory action on visceral fat accumulation by the method shown in Examples described later. As can be confirmed.
- an indicator of an inhibitory action on visceral fat accumulation by the method shown in Examples described later As can be confirmed.
- a glycoside in which glucose is bonded to the aglycone part, and that the aglycon part is 4-methylergost-7-en-3-ol is 13 C-nuclear magnetic resonance spectroscopy (NMR), etc. Can be confirmed.
- the compound of the present invention can also be produced by condensing D-glucose and 4-methylergost-7-en-3-ol.
- 4-Methylergost-7-en-3-ol can be obtained from plants by extraction and purification.
- the condensation of D-glucose and 4-methylergosto-7-en-3-ol is, for example, the method shown in the 4th edition, Experimental Chemistry Course 26, 1992 (described on pages 272, 297 and 342, respectively) Can be combined. That is, after D-glucose is completely acetylated, the anomeric position is converted to ⁇ -bromide.
- the compound of the present invention can be used as it is as an active ingredient of the visceral fat accumulation inhibitor of the present invention or a food or drink containing the same.
- a plant organic solvent extract, a hot water extract, or a compressed liquid, or a fraction thereof hereinafter referred to as “extract etc.”
- extract etc. a plant organic solvent extract, a hot water extract, or a compressed liquid, or a fraction thereof
- the pressing solution is a product obtained by collecting a plant pressing stock solution by applying a pulverized plant to a pressing machine and removing an insoluble fraction (foreign matter) using a filter or a cloth. is there.
- a pulverized plant foreign matter
- the mesophyll gel portion from which the aloe vera leaf skin has been removed is crushed using a crusher, and this is squeezed to collect the aloe vera stock solution.
- An aloe vera squeezed solution can be prepared by removing foreign matter using a filter or cloth.
- the total content of alloin and aloe emodin contained in the outer skin of aloe vera leaves is preferably 5 ppm or less.
- the extract or the like contained in the visceral fat accumulation inhibitor preferably contains at least 0.001% by mass of the compound of the present invention in a dry mass of 0.01 to 1% by mass. It is more preferable to contain 0.05 to 1% by mass.
- the extract or the like contained in the food or drink preferably contains at least 0.001% by mass of the compound of the present invention in dry mass, more preferably 0.001 to 1% by mass. It is particularly preferable to contain 0.005 to 1% by mass.
- the extract or the like may contain two or more compounds of the present invention. Further, the extract and the like can be stored or used as a powder by freeze-drying or spray-drying by a conventional method, which may be a solution.
- the visceral fat accumulation-suppressing agent of the present invention is obtained by orally administering a compound of the present invention or a composition such as an extract containing the same as it is or in combination with a pharmaceutically acceptable pharmaceutical carrier. Alternatively, it can be administered parenterally to mammals including humans.
- the compound of the present invention can be converted to a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts include both metal salts (inorganic salts) and organic salts, the list of which is ⁇ Remington's Pharmaceutical Sciences, 17th Edition, Examples are listed in “Page 1418, 1985”.
- inorganic acid salts such as hydrochloride, sulfate, phosphate, diphosphate and hydrobromide, malate, maleate, fumarate, tartrate, succinate, Organic acids such as tamate, acetate, lactate, methanesulfonate, p-toluenesulfonate, pamoate, salicylate and stearate are included without limitation.
- it may be a salt of a metal such as sodium, potassium, calcium, magnesium or aluminum, or a salt with an amino acid such as lysine.
- solvates such as hydrates of the above-mentioned compounds or pharmaceutically acceptable salts thereof are also included in the present invention.
- the formulation form of the visceral fat accumulation inhibitor of the present invention is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specifically, tablets, pills, powders, liquids, suspensions, emulsions, granules Examples thereof include capsules, capsules, syrups, suppositories, injections, ointments, patches, eye drops, and nasal drops.
- the compound of the present invention or an extract containing the compound may be used in combination with other medicinal drugs having an inhibitory action on visceral fat accumulation.
- the amount of the compound of the present invention or an extract containing the compound of the present invention contained in the visceral fat accumulation inhibitor of the present invention is not particularly limited and may be appropriately selected.
- the amount of the compound of the present invention is , at least 0.001% by weight in the formulation, preferably 0.01 to 1% by weight, particularly preferred properly is preferably set to 0.05 to 1 mass 0/0.
- visceral fat accumulation inhibitor of the present invention has an action of suppressing the accumulation of visceral fat, visceral fat-type obesity can be prevented.
- Visceral fat type obesity generally refers to a condition where the visceral fat area is 100 cm 2 or more. According to the diagnostic criteria of metabolic syndrome, the waist circumference is 85 cm or more for men and 90 cm or more for women. Case (Japan Journal of Internal Medicine, No. 94, pp. 188-203, 2005).
- the visceral fat accumulation inhibitor of the present invention is suitably used for treatment of a patient in a state where visceral fat has accumulated from normal values.
- the visceral fat accumulation-suppressing agent of the present invention is used for diseases, complications, etc. caused by visceral fat accumulation, such as lipid metabolism abnormality 'amelioration or prevention of cardiovascular diseases, etc., and these diseases' complications, etc. It is also possible to reduce the risk.
- diseases caused by vigorous visceral fat accumulation include obesity, particularly visceral fat obesity, hyperlipidemia, diabetes, hypertension, arteriosclerosis and the like.
- Complications arising from these diseases include diabetic retinopathy due to diabetes, nephropathy, neuropathy, diabetic gangrene, stroke due to hypertension, nephrosclerosis, renal failure, and stroke due to arteriosclerosis.
- cardiovascular diseases such as cerebral infarction, angina pectoris and myocardial infarction, nephropathy such as uremia, nephrosclerosis and renal failure.
- the visceral fat accumulation inhibitor of the present invention is also useful for use in preventing the onset of metabolic syndrome.
- the suppression or reduction of visceral fat accumulation is related to metabolic syndrome and related arteriosclerotic diseases, as well as lifestyle diseases such as diabetes, hypertension and hyperlipidemia, which have been pointed out as risk factors.
- it is extremely effective in preventing the onset of complications associated with these diseases.
- Metabolic syndrome in the present invention refers to the pathological condition observed in multiple risk factor syndrome, ie, hyperinsulinemia, impaired glucose tolerance or hyperglycemia, abnormal lipid metabolism, hyperlipidemia (hypertriglyceridemia, low HDL Cholesterolemia), high blood pressure, obesity, It means an arteriosclerosis-prone symptom that is combined with symptoms that are considered risk factors such as visceral fat accumulation.
- the present inventors have found that the compound of the present invention has an action of reducing hemoglobin Ale value and improving hyperglycemia (International Publication No. 2005Z095436).
- the disease to which the visceral fat accumulation-suppressing agent of the present invention is applied is preferably one in which the value of hemoglobin Ale is not higher than that of a healthy person.
- the administration time of the medicament of the present invention is not particularly limited, and the administration time can be appropriately selected according to the treatment method for the target disease.
- the dosage form is preferably determined according to the dosage form, the patient's age, sex, other conditions, the degree of symptoms of the patient, and the like.
- the dosage of the pharmaceutical agent of the present invention is appropriately selected depending on the usage, patient age, sex, disease severity, other conditions, and the like.
- the amount of the compound of the present invention as an active ingredient should be in the range of 0.001 to 50 mg / kg / day, preferably 0.01 to 1 mgZkgZ days.
- the dry mass of the extract etc. is 0.1 to: LOOOmg / kg / ⁇ , preferably 1 to: L00 mg / kg / ⁇ . It is good to use as a guide. In either case, it can be administered once or multiple times a day.
- the compound of the present invention or a composition containing the compound can be contained in a food or drink (beverage or food) to obtain a food or drink having an effect of suppressing visceral fat accumulation.
- a food or drink beverage or food
- the form and properties are not particularly limited as long as they can be taken orally without impairing the effect of the active ingredient.
- the raw materials usually used for food and drink are used except that the active ingredient is contained. And can be produced by ordinary methods.
- the amount of the compound of the present invention or an extract containing the compound of the present invention contained in the food or drink of the present invention is not particularly limited and may be appropriately selected.
- the amount of the compound of the present invention the food or drink
- the content is at least 0.0001% by mass, preferably 0.001 to 1% by mass, particularly preferably 0.001 to 1% by mass.
- “inhibition of visceral fat accumulation” means to improve or prevent various health hazards caused by visceral fat accumulation
- “Visceral fat type obesity improvement”, “Visceral fat type obesity prevention”, “Visceral fat reduction”, “Visceral fat accumulation prevention” and the like are exemplified in the present invention as the same meaning as the above “Visceral fat accumulation suppression”. be able to.
- the food and drink of the present invention is useful for improving or preventing diseases caused by visceral fat accumulation, for example, abnormal lipid metabolism such as hyperlipidemia and cardiovascular diseases. Also
- the food and drink of the present invention treats or prevents various diseases caused by visceral fat accumulation, such as complications, and risks of these diseases, such as complications. Can be reduced.
- the food / beverage product of the present invention is a food / beverage product with an indication that it is used for suppressing visceral fat accumulation, for example, “having a visceral fat accumulation-inhibiting effect displayed as“ for suppressing visceral fat accumulation ”. It is preferable to sell it as “a food or drink containing a compound” or “a food or drink containing a plant extract, which is indicated for suppressing visceral fat accumulation”.
- the indication of visceral fat accumulation inhibition in foods and drinks also has the meaning of improving visceral fat-type obesity. Conceivable. Therefore, the food and drink of the present invention can be displayed as “for visceral fat type obesity improvement”. That is, the display for suppressing visceral fat accumulation may be such a display for “improvement of visceral fat type fattening”.
- the wording used for the above display is not limited to the words “for visceral fat accumulation suppression” or “for visceral fat-type obesity improvement”, but other words.
- the wording expresses the effect of suppressing the accumulation of visceral fat or preventing or improving visceral fat obesity within the scope of the present invention.
- the "display” means all actions for informing the consumer of the use, and if the display can recall and analogize the use, the purpose of the display, the display Regardless of the content, the object to be displayed, the medium, etc., all correspond to the “display” of the present invention. However, it is preferable to display it in such an expression that the consumer can directly recognize the use.
- the act of describing the above-mentioned use in the product or the product packaging relating to the food or drink of the present invention the product or the product packaging describing the above-mentioned use is transferred, and exhibited for delivery, transfer or delivery Display or distribute the above uses in the acts of importing, advertisements on products, price lists or transaction documents, or distributing them, or describing the above uses in the contents of these information (such as the Internet) ) Examples of activities provided by the method.
- the display is preferably a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government, and that is performed in a manner based on such approval).
- promotional materials and other documents at sales sites such as packaging, containers, catalogs, brochures, and POPs.
- indications such as health foods, functional foods, enteral nutrition foods, special-purpose foods, nutritional functional foods, quasi-drugs, etc. can be exemplified.
- Approved indications for example, indications approved by foods for specified health use and similar systems can be exemplified. Examples of the latter include labeling as food for specified health use, labeling as conditionally specified food for specified health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, etc.
- Speaking of health promotion law enforcement regulations (April 30, 2003 Ministry of Health, Labor and Welfare Ordinance No. 86) labeling as food for specified health use (especially labeling of health use), and similar
- the display can be listed as a typical example.
- the compound or composition of the present invention can be produced from a plant belonging to the family Liliaceae.
- the visceral fat accumulation inhibitory effect was measured by measuring the intestinal membrane fat weight shown in Example 1 to be described later. Since the same effect was observed in the liquid extract, an attempt was made to separate and purify the components in the extract.
- the extract was examined by thin layer chromatography (manufactured by Merck, silica gel 60F254 and RP-18F2543). As a result, a separation method by normal phase silica gel column chromatography using a Kuroguchi Form Z methanol mixture was obtained. It was considered appropriate. Therefore, 400 g of silica gel 60 (Merck) was packed, and the column was poured with a solution prepared by dissolving 13 g of the extract in 1 ml of Kloform-form Z methanol mixture (1: 1).
- the yield of the crude product after removal of the solvent from each fraction was 1.44 g, 3.0 g, 1.17 g, 1.28 g, and 2.27 g, respectively.
- methanol 5: 1.
- the crude purified product A was examined using thin layer chromatography (Merck, Silica Genole 60F254 and RP-18F2543). The separation method by reversed-phase silica gel column chromatography using was considered appropriate. Therefore, the above crude purified product A was dissolved in 1 ml of black mouth form Z methanol mixture (1: 1), and Cosmo Seal 140 (manufactured by Nacalai Testa) was added.
- the aloe vera mesophyll (transparent gel part) was dried by heating, and after adding 60 ml of water to 0.3 g of the pulverized dried aloe vera powder, the mixture was heated to reflux at 95 ° C for 5 hours.
- the extract was centrifuged at 1500 rpm for 20 minutes, and the supernatant was lyophilized to obtain 75 mg of crude extract.
- This crude extract contains 3-0- ⁇ -D-darcoviranosyl 4-methylergost-7-en-3-ol. It was confirmed by thin layer chromatography.
- Example 1 ZDF (Zucker Diabetic Fatty) rats, which are obese diabetes model animals, were used, and 3-0- ⁇ -D-darcobilanosyl 4-methylergosto-7-en-1-ol, and We investigated the visceral fat accumulation inhibitory effect of Aloe vera gel press.
- the said aloe veragel pressing liquid contained 0.1 mass% of 3-O- (beta) -darcoviranosyl 4-methyl ergost 7-en-3-ol.
- the final concentration of DMSO was adjusted to 0.2%.
- a solution containing no sample was used as a negative sample.
- test sample B-1 and test sample B 2 Six-week-old male ZDF rats (purchased from US chilisuriba Co., Ltd.) were preliminarily raised for 1 month using a high fat diet (manufactured by Research Diet), and then divided into 6 groups per group. Using a sonde once a day for each group of rats, each solution of negative sample, test sample ⁇ -1, test sample A-2, test sample B-1, and test sample B-2 was weighted to 400g each. Dip lml was orally administered daily for 4 to 4 days. At this time, administration of 3-0- ⁇ -D-Darcopyranosyl 4-methylergost-7-en-1-ol in test sample A-1 and test sample A-2 The amounts were 25 ⁇ g Zkg and 2.5 ⁇ g Zkg, respectively. The dose of Aloe vera solids in test sample B-1 and test sample B 2 is 2.5 gZkg or 0.125 g / kg.
- the intestinal fat weight was measured as visceral fat.
- Table 1 shows the intestinal fat weight on the 45th day. Compared to the rat intestinal fat weight (6.83 ⁇ 1.10g) in the negative sample administration group, the test sample A-1 administration group (25 / zgZkg administration) and the test sample A-2 administration group (2.5 / zgZkg administration), the fat mass was 3.15 ⁇ 0.28g and 4.99 ⁇ 0.53g, respectively, indicating 46.2% and 73.1% of the negative sample administration group, respectively, statistically A significant inhibitory effect on visceral fat accumulation was observed. In addition, in the test sample B 1 administration group (2.5 gZkg administration) and the test sample B 2 administration group (0.125 gZkg administration), the monthly fat mass was 4.72 ⁇ 0.666 g and 4.75 ⁇ 0, respectively.
- Test sample A 1 3. 15 ⁇ 0. 28 * 0, 00003 Test sample A— 2 4. 99 ⁇ 0. 53 * 0. 007 Test sample B— 1 4. 72 ⁇ 0. 66 * 0. 0012 Test sample B— 2 4. 75 ⁇ 0. 79 * 0. 0039
- the Aloe vera gel squeezed liquid, 3 - ⁇ - ⁇ - D - Darukobiranoshiru 4 was confirmed that methyl ergo strike one 7 E down one 3-ol containing 0.1 mass 0/0.
- the final concentration of DMSO was adjusted to 0.2%.
- a solution containing no sample was used as a negative sample.
- 6-week-old male ZDF rats purchased from US chilisuriba Co., Ltd.
- Rats in each group were orally administered once a day for 44 days with a sample of test sample C, test sample D, and negative sample, each in an amount of 400 g body weight and 1 ml each.
- the dose of 3-O- ⁇ -D-darcoviranosyl 4-methylergost-7-en-3-ol in test sample C was 37.5 gZkg.
- the dose of Aloe vera solid in test sample D was 3.75 gZkg.
- the body weight of the rats on the 42nd day was also measured as the administration start force, and the difference from the body weight before the start of administration was taken as the body weight gain.
- the weight of food consumed during the day was measured at a rate of once a week from the start of administration, and this average value was taken as the amount of food consumed per day.
- Table 2 shows the amount of food consumed per day and the amount of gain during 42 days.
- the group to which test sample C and test sample D were administered had no significant increase or decrease in food consumption compared to the group to which negative sample was administered.
- the weight gain (weight gain) was also almost the same as in the group receiving the negative sample. Therefore, it was found that 3-O- ⁇ -D-Dalcobilanosyl-4-methylergosto 7-en-3-ol had no effect on rat food intake and weight gain! /.
- the present invention provides a visceral fat accumulation inhibitor that is capable of maintaining a standard body weight without losing weight, and effective in suppressing obesity progression and 01 without excessive dietary restriction, and the like. It is possible to provide functional foods and beverages such as foods for specified health use containing visceral fat accumulation inhibitors, and diseases and complications caused by visceral fat accumulation such as abnormal lipid metabolism 'circulatory diseases, etc. It is also possible to reduce or reduce the risk of such diseases and complications. It also has the effect of preventing the development of metabolic syndrome and lifestyle-related diseases such as diabetes, hypertension, and hyperlipidemia, which have been pointed out as risk factors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/913,022 US7846905B2 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
CA2611086A CA2611086C (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
CN2006800243134A CN101212979B (zh) | 2005-09-22 | 2006-09-21 | 内脏脂肪蓄积抑制剂 |
ES06810359T ES2730833T3 (es) | 2005-09-22 | 2006-09-21 | Agente para inhibir la acumulación de grasa visceral |
JP2007536542A JP4162703B2 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
EP06810359.7A EP1927361B1 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
AU2006293136A AU2006293136B2 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
HK08111296.0A HK1119402A1 (en) | 2005-09-22 | 2008-10-13 | Visceral fat accumulation inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-275171 | 2005-09-22 | ||
JP2005275171 | 2005-09-22 | ||
JP2005-287887 | 2005-09-30 | ||
JP2005287887 | 2005-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007034851A1 true WO2007034851A1 (ja) | 2007-03-29 |
Family
ID=37888894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/318685 WO2007034851A1 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7846905B2 (ja) |
EP (1) | EP1927361B1 (ja) |
JP (1) | JP4162703B2 (ja) |
KR (2) | KR20090120018A (ja) |
CN (1) | CN101212979B (ja) |
AU (1) | AU2006293136B2 (ja) |
CA (1) | CA2611086C (ja) |
ES (1) | ES2730833T3 (ja) |
HK (1) | HK1119402A1 (ja) |
RU (1) | RU2372920C2 (ja) |
WO (1) | WO2007034851A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2004105770A1 (en) * | 2003-05-31 | 2004-12-09 | Forbes Medi-Tech Inc. | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes |
WO2005095436A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 |
WO2006123465A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
WO2006123464A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4735935A (en) | 1985-12-17 | 1988-04-05 | Carrington Laboratories, Inc. | Process for preparation of aloe products products, produced thereby and compositions thereof |
JP3029907B2 (ja) | 1991-12-20 | 2000-04-10 | 理化学研究所 | 抗肥満剤 |
JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
JP3873097B2 (ja) | 1997-11-06 | 2007-01-24 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
NZ330439A (en) | 1998-05-15 | 2001-01-26 | Immuno Lab Ltd | Dietary supplements comprising collagen hydrosylate, aloe vera, hydroxy citric acid, L-carnitine and water for weight loss |
US6506387B1 (en) * | 1999-04-28 | 2003-01-14 | Paxa N.V. | Method for preparing aloin by extraction |
JP3858055B2 (ja) | 2000-02-29 | 2006-12-13 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
AU2003261860A1 (en) * | 2002-08-30 | 2004-03-19 | Masashi Komeda | Composition for protecting organ, tissue or cell and utilization thereof |
JP2005015425A (ja) | 2003-06-27 | 2005-01-20 | Kao Corp | 脂質代謝改善剤 |
CA2546180A1 (en) * | 2003-11-26 | 2005-06-09 | Universitaet Bern | Plant extracts for the treatment of increased bone resorption |
CA2611181C (en) * | 2005-09-22 | 2010-11-02 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
WO2007043302A1 (ja) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | インスリン抵抗性改善剤 |
-
2006
- 2006-09-21 CA CA2611086A patent/CA2611086C/en active Active
- 2006-09-21 JP JP2007536542A patent/JP4162703B2/ja active Active
- 2006-09-21 CN CN2006800243134A patent/CN101212979B/zh active Active
- 2006-09-21 ES ES06810359T patent/ES2730833T3/es active Active
- 2006-09-21 RU RU2007145189/15A patent/RU2372920C2/ru not_active IP Right Cessation
- 2006-09-21 EP EP06810359.7A patent/EP1927361B1/en active Active
- 2006-09-21 WO PCT/JP2006/318685 patent/WO2007034851A1/ja active Application Filing
- 2006-09-21 KR KR1020097023663A patent/KR20090120018A/ko not_active Application Discontinuation
- 2006-09-21 US US11/913,022 patent/US7846905B2/en active Active
- 2006-09-21 KR KR1020077025283A patent/KR100941015B1/ko active IP Right Grant
- 2006-09-21 AU AU2006293136A patent/AU2006293136B2/en active Active
-
2008
- 2008-10-13 HK HK08111296.0A patent/HK1119402A1/xx not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2004105770A1 (en) * | 2003-05-31 | 2004-12-09 | Forbes Medi-Tech Inc. | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes |
WO2005095436A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 |
WO2006123465A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
WO2006123464A1 (ja) * | 2005-05-17 | 2006-11-23 | Morinaga Milk Industry Co., Ltd. | 膵臓機能改善のための医薬又は飲食品 |
Non-Patent Citations (1)
Title |
---|
PANOSYAN A.G. ET AL.: "Sterols and sterol glycosides of Bryonia alba", KHIMIYA PRIRODNYKH SOEDINENII, no. 3, 1977, pages 353 - 360, XP003010652 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
JP4580041B2 (ja) * | 2008-11-19 | 2010-11-10 | 森永乳業株式会社 | 抗酸化剤 |
JPWO2010058794A1 (ja) * | 2008-11-19 | 2012-04-19 | 森永乳業株式会社 | 抗酸化剤 |
RU2465909C1 (ru) * | 2008-11-19 | 2012-11-10 | Моринага Милк Индастри Ко., Лтд. | Антиоксидант |
AU2009318455B2 (en) * | 2008-11-19 | 2012-11-29 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
US8486899B2 (en) | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
Also Published As
Publication number | Publication date |
---|---|
HK1119402A1 (en) | 2009-03-06 |
RU2372920C2 (ru) | 2009-11-20 |
KR100941015B1 (ko) | 2010-02-05 |
CA2611086C (en) | 2011-06-21 |
ES2730833T3 (es) | 2019-11-12 |
US7846905B2 (en) | 2010-12-07 |
EP1927361B1 (en) | 2019-04-03 |
CN101212979A (zh) | 2008-07-02 |
EP1927361A1 (en) | 2008-06-04 |
EP1927361A4 (en) | 2012-12-12 |
CA2611086A1 (en) | 2007-03-29 |
JPWO2007034851A1 (ja) | 2009-03-26 |
AU2006293136B2 (en) | 2010-01-14 |
CN101212979B (zh) | 2013-07-17 |
AU2006293136A1 (en) | 2007-03-29 |
US20090069254A1 (en) | 2009-03-12 |
RU2007145189A (ru) | 2009-06-10 |
KR20080017303A (ko) | 2008-02-26 |
KR20090120018A (ko) | 2009-11-23 |
JP4162703B2 (ja) | 2008-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006035525A1 (ja) | 高血糖改善のための医薬及び飲食品 | |
US8486462B2 (en) | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent | |
KR100941016B1 (ko) | 인슐린 저항성 개선제 | |
JP4164538B2 (ja) | 内臓脂肪蓄積抑制剤 | |
JP4065016B2 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
JP4162703B2 (ja) | 内臓脂肪蓄積抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680024313.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007536542 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006810359 Country of ref document: EP Ref document number: 4691/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11913022 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006293136 Country of ref document: AU Ref document number: 1020077025283 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006293136 Country of ref document: AU Date of ref document: 20060921 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006293136 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2611086 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007145189 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097023663 Country of ref document: KR |